

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 April 2025 (03.04.2025)



(10) International Publication Number
WO 2025/068951 A1

(51) International Patent Classification:

C07D 209/08 (2006.01) C07D 405/12 (2006.01)
C07D 401/12 (2006.01) C07D 405/14 (2006.01)
C07D 401/14 (2006.01) A61K 31/404 (2006.01)
C07D 403/12 (2006.01) A61P 27/02 (2006.01)

(21) International Application Number:

PCT/IB2024/059431

(22) International Filing Date:

26 September 2024 (26.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/586,620 29 September 2023 (29.09.2023) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **CZABANIUK, Lara C.**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GOMMER-MANN, Nina**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **HURTH, Konstanze**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **JACQUIER, Sébastien**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **LABBE-GIGUERE, Nancy**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **MARGREY, Kaila Ashley**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SCHOEN, Adeline**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SENDZIK, Martin**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **VULPETTI, Anna**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every


kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF

(57) Abstract: Provided herein are compounds of Formula (I) and pharmaceutical compositions there useful for treating diseases or disorders mediated by the complement factor B.



WO 2025/068951 A1